Multiple Sclerosis and Psoriasis
Dr Cohen examines the complex relationship between psoriasis and multiple sclerosis (MS), focusing on the impact of TNF-alpha inhibitors. Studies show that TNF inhibitors not only lack benefit in MS but may also worsen disease activity and induce demyelination.
Jeffrey M. Cohen, MD is a board-certified medical dermatologist and the director of the psoriasis treatment program at the Yale School of Medicine in New Haven, CT.
© 2025 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of The Dermatologist or HMP Global, their employees, and affiliates.
The APP Institute is dedicated to educating and informing advanced practice providers on clinical topics and practical issues to support the profession and improve the quality of patient care across the spectrum of dermatology.
The Derm APP is designed for Advanced Practice Providers who specialize in Dermatology, to further their education and increase their knowledge to achieve better patient outcomes. Explore cutting-edge research, innovative treatment options, and new therapeutic methods, while remaining focused on the fundamental principles and terminology associated with dermatology. Engage year-round with The Dermatologist to access clinical insights, interactive features, research news updates, accredited continuing education programs, and more.
